IPSCHealthcare · BiotechnologyIPSC Stock Forecast: Century Therapeutics, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Century Therapeutics, Inc. hold a median 12-month price target of $4.5 — +127.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 1 Aug 2026 — in the lower half.
IPSC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Century Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (90): The shares have been drifting up relative to others.
Growth (16): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Century Therapeutics, Inc. — and when they’d sell — is the membership.
IPSC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IPSC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +127.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 May 2026 | Mizuho | Initiates | Outperform | $8.00 |
| 21 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Jan 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Nov 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 16 May 2025 | Chardan Capital | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Mar 2025 | Guggenheim | Reiterates | Buy | — |
| 24 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 21 Mar 2025 | Guggenheim | Maintains | Buy | — |
| 20 Mar 2025 | Piper Sandler | Maintains | Overweight | — |
| 22 Jan 2025 | Guggenheim | Reiterates | Buy | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Dec 2024 | Piper Sandler | Maintains | Overweight | — |
| 7 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 June 2024 | Piper Sandler | Maintains | Overweight | — |
| 4 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Apr 2024 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IPSC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Century Therapeutics, Inc. (IPSC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −14.4×
- Price / sales
- 3.3×
- Price / book
- 1.4×
- EV / EBITDA
- −2.7×
Cheaper than 95% of US stocks
Cheaper than 38% of US stocks
Cheaper than 60% of US stocks
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −9.6%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 26% of US stocks
Higher than 30% of US stocks
- Return on equity
- −42.7%
- Return on assets
- −22.3%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
IPSC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IPSC appears on the weeks it earns a place.
Frequently asked questions about IPSC stock
What is the IPSC stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Century Therapeutics, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IPSC stock a buy right now?
Of the 5 analysts covering Century Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Century Therapeutics, Inc. 47 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IPSC?
As at 1 Aug 2026, Century Therapeutics, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).
Will IPSC stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +127.3% from the last close, and Ticker Nerd's factor model ranks Century Therapeutics, Inc. 47 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IPSC stock forecast for 2030?
No analyst covering Century Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IPSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.
How has IPSC stock performed over the past year?
Century Therapeutics, Inc. returned +272.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Century Therapeutics, Inc. do?
Century Therapeutics Inc. is a biotechnology company that focuses on developing innovative cell therapies for cancer treatment.
About Century Therapeutics, Inc.
Century Therapeutics Inc. is a biotechnology company that focuses on developing innovative cell therapies for cancer treatment. The company's core mission centers around harnessing the potential of induced pluripotent stem cells (iPSCs) to create highly effective, off-the-shelf cellular therapies. By leveraging iPSCs, Century Therapeutics aims to produce uniformly engineered allogeneic cell products designed to target and eliminate cancer cells with precision. Century Therapeutics operates primarily within the healthcare and biopharmaceutical industry, specifically targeting the oncology sector. It seeks to address unmet medical needs by offering more accessible and potent therapeutic solutions compared to traditional cancer treatments. The company's research and development efforts are focused on using its technology platform to generate natural killer (NK) cells and T cells that possess enhanced tumor-fighting capabilities. In the financial market, Century Therapeutics plays a vital role in driving innovation in cancer treatment solutions. It represents a segment of biotechnology firms dedicated to advancing cellular immunotherapies, potentially transforming the landscape of cancer care and treatment. The company's work contributes to the growing field of cell therapy, highlighting the importance of biotechnological advances in modern medicine.
CEO Dr. Brent Pfeiffenberger M.B.A., Pharm.D. · 78 employees · United States · https://www.centurytx.com